NEW YORK, NY / ACCESSWIRE / October 5, 2021 / The Law Offices of Vincent Wong announce that class actions have commenced on behalf of certain shareholders in the following companies. If you suffered a loss you have until the lead plaintiff deadline to request that the court appoint you as lead plaintiff. There will be no obligation or cost to you.
Selectquote, Inc. (NYSE:SLQT)
If you suffered a loss, contact us at: https://www.wongesq.com/pslra-1/selectquote-inc-loss-submission-form?prid=20130&wire=1
Lead Plaintiff Deadline: October 15, 2021
Class Period: February 8, 2021 - May 11, 2021
Allegations against SLQT include that: (1) SelectQuote's 2019 cohort was underperforming; (2) as a result, the Company's financial results would be adversely impacted; and (3) as a result of the foregoing, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.
Annovis Bio, Inc. (NYSE:ANVS)
If you suffered a loss, contact us at: https://www.wongesq.com/pslra-1/annovis-bio-inc-loss-submission-form?prid=20130&wire=1
Lead Plaintiff Deadline: October 18, 2021
Class Period: May 21, 2021 - July 28, 2021
Allegations against ANVS include that: (1) Annovis's ANVS401 (Posiphen), an orally administrated drug which purportedly inhibited the synthesis of neurotoxic proteins that are the main cause of neurodegeneration, did not show statistically significant results across two patient populations as to factors such as orientation, judgement, and problem solving; and (2) as a result of the foregoing, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.
Cassava Sciences, Inc. (NASDAQ:SAVA)
If you suffered a loss, contact us at: https://www.wongesq.com/pslra-1/cassava-sciences-inc-loss-submission-form?prid=20130&wire=1
Lead Plaintiff Deadline: October 26, 2021
Class Period: September 14, 2020 - August 27, 2021
Allegations against SAVA include that: (a) the quality and integrity of the scientific data supporting Cassava's claims for simufilam's, a small molecule drug designed to treat Alzheimer's disease, efficacy had been overstated; (b) the scientific data supporting Cassava's claims for simufilam's efficacy were biased; and (c) as a result of the foregoing, Defendants' positive statements during the Class Period about the Company's business metrics and financial prospects and the likelihood of Food and Drug Administration approval were false and misleading and/or lacked a reasonable basis.
To learn more contact Vincent Wong, Esq. either via email vw@wongesq.com or by telephone at 212.425.1140.
Vincent Wong, Esq. is an experienced attorney who has represented investors in securities litigations involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT:
Vincent Wong, Esq.
39 East Broadway
Suite 304
New York, NY 10002
Tel. 212.425.1140
Fax. 866.699.3880
E-Mail: vw@wongesq.com
SOURCE: The Law Offices of Vincent Wong
View source version on accesswire.com:
https://www.accesswire.com/666866/SHAREHOLDER-ALERT-SLQT-ANVS-SAVA-The-Law-Offices-of-Vincent-Wong-Reminds-Investors-of-Important-Class-Action-Deadlines
